Unicycive Therapeutics earnings were -$36.2M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest UNCY earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$7.0M, up 306.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, UNCY reported annual earnings of -$26.6M, with -29.8% growth.
Unicycive Therapeutics Earnings Reports & History FAQ
What were Unicycive Therapeutics's earnings last quarter?
On UNCY's earnings call on Nov 16, 2026, Unicycive Therapeutics (NASDAQ: UNCY) reported Q3 2026 earnings per share (EPS) of -$0.25, up 24.24% year over year. Total UNCY earnings for the quarter were -$7.00 million. In the same quarter last year, Unicycive Therapeutics's earnings per share (EPS) was -$0.33.
Is Unicycive Therapeutics profitable or losing money?
As of the last Unicycive Therapeutics earnings report, Unicycive Therapeutics is currently losing money. Unicycive Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2026 was -$36.21 million, a 8.37% increase year over year.
What was UNCY's earnings growth in the past year?
As of Unicycive Therapeutics's earnings date in Nov 16, 2026, Unicycive Therapeutics's earnings has grown year over year. UNCY earnings in the past year totalled -$36.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.